Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 par value ATRC NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ¨ ...

AtriCure, Inc. (NASDAQ:ATRC) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan John Newman - Canaccord Genuity John McAulay - Stifel Financial Corp. Sam Eiber - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Suraj Kalia - Oppenheimer & Co. Joseph Conway - Needham & Company Operator Good a ...

AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.33%. A quarter ago, it was expected that this medical device maker would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%.Over the last four quarters, the company has ...

Exhibit 99.1 For immediate release July 30, 2024 AtriCure Reports Second Quarter 2024 Financial Results • Worldwide revenue of $116.3 million – an increase of 15.2% year over year • Positive cash flow generation of $8.1 million in second quarter 2024 MASON, Ohio, July 30, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2024 f ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 par value ATRC NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ ...

AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan William Plovanic - Canaccord Genuity Marie Thibault - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Mike Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Good afternoon and welcome to AtriCure’s First ...

For the quarter ended March 2024, AtriCure (ATRC) reported revenue of $108.85 million, up 16.4% over the same period last year. EPS came in at -$0.25, compared to -$0.23 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $106.52 million, representing a surprise of +2.19%. The company delivered an EPS surprise of -19.05%, with the consensus EPS estimate being -$0.21.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...

Exhibit 99.1 For immediate release May 1, 2024 AtriCure Reports First Quarter 2024 Financial Results • Worldwide revenue of $108.9 million – an increase of 16.4% year over year MASON, Ohio, May 1, 2024 – AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results. "We are proud to announce a strong start to 2024, marked by ...

AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Conference Call February 15, 2024 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JP Morgan Simon Negin - UBS Matthew O’Brien - Piper Sandler Sam Eiber - BTIG Joseph Conway - Needham Daniel Stauder - JMP Suraj Kalia - Oppenheimer & Company Operator Good afternoon, and welcome to AtriCure’s ...

AtriCure (ATRC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this medical device maker would post a loss of $0.30 per share when it actually produced a loss of $0.20, delivering a surprise of 33.33%.Over the last four quarters, the company has sur ...